Coffee and the caffeine in it were long-considered a risk for patients with certain heart conditions. But a recent study ...
Tri-City Cardiology, a Phoenix-based cardiology group among the largest and most respected in the country, has expanded its ...
As the holiday season ramps up with parties, big meals and celebratory drinks, doctors are reminding men not to ignore their ...
I felt fine, but my Whoop data told a different story. Paying attention led to early detection and a successful treatment.
Doctors typically recommend that people with heart issues like A-Fib avoid caffeine out of fear that it will trigger symptoms. But a study by UC San Francisco and the University of Adelaide concluded ...
After claiming its approval in Europe earlier this year, Abbott has secured the FDA’s go-ahead for its Volt pulsed field ablation system for irregular heart rhythms, a step forward in an | With the U.
BSX builds momentum in PFA as FARAPULSE posts strong growth, and new trial results and expanded FDA labeling boost its AF treatment push.
Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.
In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% ...
Wellbeing Whisper on MSN
Sweetened drinks tied to higher AFib risk: What you can do
One can easily come to a conclusion regarding why it is a great change for one’s heart when they switch from drinking a normal soft drink to a “diet” soft drink. Nevertheless, it is important to note ...
A routine blood test identified abnormalities, leading to follow-up tests. A hematologist diagnosed Evans with early-stage ...
News-Medical.Net on MSN
Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL
Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results